P&G in China
This article was originally published in The Tan Sheet
Executive Summary
Firm announces $1.8 bil. purchase of remaining 20% stake in China joint venture from partner Hutchison Whampoa China. The deal was announced May 11 and is expected to close June 18. CEO A.G. Lafley said "it is the right time for us to assume full ownership" of the China venture, and that recent positive results demonstrate P&G has the "in-depth understanding of local consumers and retailers in China to continue to build this fast-growing business." China is one area where P&G has sought to localize its supply chain, marketing and management (1"The Tan Sheet" May 3, 2004, p. 6)...
You may also be interested in...
P&G Leverages Prilosec OTC, Oral Care Products To Increase Market Leads
Procter & Gamble's Prilosec OTC has garnered nearly a quarter share of the over-the-counter stomach remedy category
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.